Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation.

Cancers·2026
Same author

Editorial: Liquid-biopsy-guided biomarker and drug discovery.

Frontiers in pharmacology·2024
Same author

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2.

ACS omega·2021
Same author

Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.

Cancer gene therapy·2021
Same author

Synthesis of NVS-BPTF-1 and evaluation of its biological activity.

Bioorganic & medicinal chemistry letters·2021

Related Experiment Video

Updated: Feb 17, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.6K

Novel approaches to targeting BRD4.

Olesya A Kharenko1, Henrik C Hansen1

  • 1Zenith Epigenetics, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.

Drug Discovery Today. Technologies
|December 14, 2017
PubMed
Summary
This summary is machine-generated.

Novel epigenetic drugs targeting bromo and extra-terminal (BET) bromodomains, like BRD4, are advancing in oncology. Proteolytic and irreversible inhibitors offer new tools to study cancer biology and may soon enter clinical trials.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.2K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.3K

Related Experiment Videos

Last Updated: Feb 17, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.6K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.2K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.3K

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Bromo and extra-terminal (BET) bromodomains, including BRD4, are emerging epigenetic targets in cancer therapy.
  • Traditional reversible small molecule inhibitors have limitations.
  • Novel therapeutic strategies are needed for enhanced cancer treatment.

Purpose of the Study:

  • To explore novel alternatives to reversible small molecule inhibitors for BET bromodomains.
  • To evaluate the potential of proteolytic targeting BET agents and irreversible binding inhibitors.
  • To highlight the utility of these novel agents as tools for biological research.

Main Methods:

  • Review of recent advancements in BET bromodomain inhibition.
  • Analysis of preclinical data for novel BET inhibitor classes.
  • Discussion of emerging therapeutic strategies in oncology.

Main Results:

  • Emergence of novel BET bromodomain inhibitors, including proteolytic targeting agents and irreversible binders.
  • Preclinical data support the potential advantages of these new agents.
  • These novel inhibitors show promise for future clinical development.

Conclusions:

  • Novel BET bromodomain inhibitors represent a promising frontier in epigenetic oncology.
  • Proteolytic and irreversible inhibitors offer new avenues for cancer therapy and biological investigation.
  • These agents are poised for near-future clinical translation based on supportive preclinical evidence.